CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Fundamental Analysis

NASDAQ:CNTB • KYG235491019

2.65 USD
-0.25 (-8.62%)
At close: Feb 20, 2026
2.69 USD
+0.04 (+1.51%)
After Hours: 2/20/2026, 8:25:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CNTB. CNTB was compared to 521 industry peers in the Biotechnology industry. CNTB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CNTB had negative earnings in the past year.
  • In the past 5 years CNTB always reported negative net income.
  • CNTB had a negative operating cash flow in each of the past 5 years.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M -1B

1.2 Ratios

  • CNTB has a Return On Assets of -23.20%. This is in the better half of the industry: CNTB outperforms 73.32% of its industry peers.
  • CNTB's Return On Equity of -28.22% is fine compared to the rest of the industry. CNTB outperforms 77.74% of its industry peers.
Industry RankSector Rank
ROA -23.2%
ROE -28.22%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CNTB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CNTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of -0.33, we must say that CNTB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.33, CNTB perfoms like the industry average, outperforming 59.31% of the companies in the same industry.
  • CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACCN/A
WACC8.71%
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • CNTB has a Current Ratio of 5.48. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.48, CNTB is in line with its industry, outperforming 58.35% of the companies in the same industry.
  • A Quick Ratio of 5.48 indicates that CNTB has no problem at all paying its short term obligations.
  • CNTB has a Quick ratio (5.48) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.90%, which is quite impressive.
EPS 1Y (TTM)74.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CNTB will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.88% on average per year.
  • CNTB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.23% yearly.
EPS Next Y-212.62%
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%
EPS Next 5Y10.88%
Revenue Next Year-99.83%
Revenue Next 2Y-35.07%
Revenue Next 3Y-10.13%
Revenue Next 5Y-18.23%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A cheap valuation may be justified as CNTB's earnings are expected to decrease with -30.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CNTB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (2/20/2026, 8:25:23 PM)

After market: 2.69 +0.04 (+1.51%)

2.65

-0.25 (-8.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners39.14%
Inst Owner Change397.79%
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap147.66M
Revenue(TTM)26.03M
Net Income(TTM)-15.63M
Analysts85.45
Price Target8.06 (204.15%)
Short Float %0.84%
Short Ratio2.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.2%
Min EPS beat(2)69.43%
Max EPS beat(2)74.98%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1733.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.67
P/FCF N/A
P/OCF N/A
P/B 2.67
P/tB 2.67
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.47
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.2%
ROE -28.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z -0.33
F-ScoreN/A
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)182.41%
Cap/Depr(5y)444.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-212.62%
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%
EPS Next 5Y10.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.83%
Revenue Next 2Y-35.07%
Revenue Next 3Y-10.13%
Revenue Next 5Y-18.23%
EBIT growth 1Y71.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.54%
OCF growth 3YN/A
OCF growth 5YN/A

CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ

Can you provide the ChartMill fundamental rating for CONNECT BIOPHARMA HOLDINGS L?

ChartMill assigns a fundamental rating of 2 / 10 to CNTB.


What is the valuation status for CNTB stock?

ChartMill assigns a valuation rating of 0 / 10 to CONNECT BIOPHARMA HOLDINGS L (CNTB). This can be considered as Overvalued.


What is the profitability of CNTB stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CONNECT BIOPHARMA HOLDINGS L?

The Earnings per Share (EPS) of CONNECT BIOPHARMA HOLDINGS L (CNTB) is expected to decline by -212.62% in the next year.